
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral rinse containing 2-deoxy-D-glucose, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No product listing under the name 2-deoxy-D-glucose was found in the directory.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
2-Deoxy-D-glucose is an investigational glucose analog that blocks glycolysis; no FDA-approved drug product contains it, and it is compounded only by prescription.
2-Deoxy-D-glucose (2-DG) is a naturally occurring glucose analog in which one hydroxyl group is replaced by hydrogen. Cells take it up like glucose, but it cannot be fully metabolized, so it competitively inhibits glycolysis and also interferes with N-glycosylation of proteins. There is no FDA-approved drug product containing 2-DG, and a DailyMed label search returns no products for it. Its radiolabeled relative, fludeoxyglucose F 18 injection, is an FDA-approved imaging agent used for PET scans in cancer, heart and epilepsy evaluation; that is a different product. FDA lists "Deoxy-D-Glucose" among bulk substances nominated for 503A compounding that remain under evaluation (Category 1). Compounded preparations are not FDA-approved and require a prescription.
Because 2-DG has no FDA label, there is no labeled boxed warning, contraindication list or interaction table. A 2023 peer-reviewed review reports that, at doses above those found tolerable in people, side effects included reversible high blood sugar, gastrointestinal bleeding and QTc prolongation, a change in heart rhythm seen on an ECG, and states that the safest doses, toxicity and interactions of 2-DG still need investigation. Tell your prescriber about any heart rhythm problem, diabetes, stomach or bowel bleeding, and every medicine and supplement you take. No pregnancy or breastfeeding data were found in the sources reviewed, so discuss pregnancy or nursing with your prescriber before use. For black stools, fainting, a racing or irregular heartbeat, or other side effects, talk to your prescriber or pharmacist.
2-DG is a nonmetabolizable glucose analog and a competitive inhibitor of glycolysis. Per the Singh 2023 review, its toxic effects stem mainly from blocking glycosylation rather than glycolysis, and a ketogenic diet increased tolerance to glycolysis inhibitors in reported work. It has been studied as an anticancer agent and radiosensitizer, as an antiviral, as an anti-inflammatory, and for antiseizure effects and slowing of epilepsy progression in animal models. The Drugs Controller General of India granted emergency use approval for 2-DG in COVID-19 on May 1, 2021; it has no FDA approval for any indication. Reported adverse effects above the tolerable dose range include reversible hyperglycemia, gastrointestinal bleeding and QTc prolongation, and the review calls for further work on dosing, mechanism, toxicity and interactions. There is no labeled indication; any use is off-label and investigational, and dosing is per prescriber. Monitoring considerations that follow from the reported adverse effects include blood glucose, ECG with QTc, and signs of gastrointestinal bleeding. FDA lists "Deoxy-D-Glucose" in Category 1 of its 503A nominations (updated May 14, 2026), meaning it is under evaluation and FDA does not intend to act against 503A compounders using it if conditions are met. 2-DG is not a controlled substance.
Measure the amount shown on your label with the cup or syringe provided. Swish it around your mouth for the time on your label, often 30 seconds or longer, then spit it out unless your label says to swallow. Do not eat, drink or rinse with water for a while afterward as directed. Shake the bottle first if your label says to.
Oral rinses are aqueous. Under USP <795>, a preserved rinse usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Rinse mouth